Study Finds Handheld Electro-Shockers Can Pose Risk for Individuals with Cardiac Implants

Research has found that handheld electro-shockers commonly used for self defense can potentially interact with cardiac implantable electronic devices (CIEDs) such as pacemakers, putting individuals at risk. The study in Heart Rhythm, the official journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society, and the Pediatric & Congenital Electrophysiology Society, published by Elsevier, shows that the individual interactive risk is primarily based on the applied voltage, but also on the manufacturer and type of implanted CIED.

The use of TASER pistols by security forces has been controversial because of associated health risks for subjects receiving a TASER shock. In contrast to TASER pistols, which shoot electrical darts over a distance of up to 10 meters and transmit electrical currents through large parts of a person’s body, a handheld electro-shocker delivers energy superficially by directly applying the device to a target. The handheld electro-shockers tested in this study are legal to own and carry in most countries and therefore, patients with CIEDs might have an increased risk of coming into contact with these devices. This is the first time a study has evaluated the effects of these electro-shockers on CIEDs.

Lead investigator Felix K. Wegner, MD, Department of Cardiology II – Electrophysiology, University Hospital Muenster, Germany, says, "Current literature and manufacturer guidelines don't fully address patients' concerns about living with a CIED. To investigate the interaction between electro-shockers and cardiac devices, we devised an experimental model in which six pacemakers and ten implantable cardioverter-defibrillators from different manufacturers were implanted in a subcutaneous and submuscular location in an isolated section of a porcine chest and connected to an interactive heart simulator. Subsequently, three types of electro-shockers were applied to the chest."

Data analysis showed that the electro-shocker with the highest applied voltage (“PowerMax,” 500,000 volt) had a high potential of interaction with all tested CIEDs. Depending on the CIED manufacturer, there was a relevant risk of inadequate shock delivery by implantable cardioverter-defibrillators. Conversely, smaller handheld electro-shockers with lower applied voltages (“Electric Guard,” 250,000 volt and “Bikenda,” <50,000 volt) had a significantly reduced risk of interaction.

Dr. Wegner notes, "We were surprised to find that submuscular CIED implantation did not significantly reduce the risk of interaction when compared to subcutaneous CIED implantation. Additionally, we expected the distance between the electro-shocker application and the CIED implantation site to have a greater impact on the risk of interaction than it did in the present study. These unexpected findings indicate that electro-shocker applications to a large part of a patient with a CIED’s body may pose a relevant risk of interaction with the respective CIED.”

Senior author Lars Eckardt, Department of Cardiology II – Electrophysiology, University Hospital Muenster, Germany, concludes, “Commercially available handheld electro-shockers pose a relevant risk of interaction when applied in proximity to CIEDs. The risk of interaction is primarily dependent on applied voltage but resulting changes in cardiac device behavior differ according to the respective manufacturer. In this experimental study, which is the result of an excellent and fruitful cooperation with our local traumatologists, no signs of cardiac device damage were noted due to handheld electro-shocker application. Further research is warranted to evaluate whether our findings are transferable to all current and legacy CIED systems."

Notes for editors

The article is “Effects of handheld electro-shockers on cardiac implantable electronic devices," by Felix K. Wegner, MD, Lena Breuer, MS, Julian Wolfes, MD, Dennis Korthals, MD, Christian Ellermann, MD, Moritz Martinovic, MSc, Christoph Kittl, MD, Florian Reinke, MD, Gerrit Frommeyer, MD, and Lars Eckardt, MD (https://doi.org/10.1016/j.hrthm.2025.02.025). The article appears online in advance of Heart Rhythm, volume 22, issue 5 (May 2025), published by Elsevier.

It is openly available at https://www.heartrhythmjournal.com/article/S1547-5271(25)00194-8/fulltext.

Full text of the article is also available to credentialed journalists upon request; contact Jane Grochowski at +1 406 542 8397 or [email protected]. Journalists wishing to interview the authors should contact Felix K. Wegner, MD, at [email protected].

About Heart Rhythm

Heart Rhythm, the official Journal of the Heart Rhythm Society, the Cardiac Electrophysiology Society, and the Pediatric & Congenital Electrophysiology Society, is a unique journal for fundamental discovery and clinical applicability. It integrates the entire cardiac electrophysiology (EP) community from basic and clinical academic researchers, private practitioners, engineers, allied professionals, industry, and trainees, all of whom are vital and interdependent members of our EP community. www.heartrhythmjournal.com

About the Heart Rhythm Society

The Heart Rhythm Society is the international leader in science, education, and advocacy for cardiac arrhythmia professionals and patients, and the primary information resource on heart rhythm disorders. Its mission is to improve the care of patients by promoting research, education, and optimal healthcare policies and standards. The Heart Rhythm Society is the preeminent professional group representing more than 8,000 specialists in cardiac pacing and electrophysiology from more than 94 countries. www.HRsonline.org

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @ElsevierConnect.